United Immunity (Tokyo, Japan) enters into the Research Collaboration Agreement with AstraZeneca.
See further information on the Japanese press release.
(https://www.astrazeneca.co.jp/media/press-releases1/2024/2024072601.html)
United Immunity develops its proprietary active targeting pullulan lipid nanoparticle (LNP) selective to myeloid cells as its Myeloid Targeting PlatformTM .